Free Trial

ResMed (RMD) Competitors

$213.23
+3.05 (+1.45%)
(As of 11:19 AM ET)

RMD vs. BSX, MDT, BDX, EW, DXCM, IDXX, STE, HOLX, BAX, and PODD

Should you be buying ResMed stock or one of its competitors? The main competitors of ResMed include Boston Scientific (BSX), Medtronic (MDT), Becton, Dickinson and Company (BDX), Edwards Lifesciences (EW), DexCom (DXCM), IDEXX Laboratories (IDXX), STERIS (STE), Hologic (HOLX), Baxter International (BAX), and Insulet (PODD). These companies are all part of the "health care equipment" industry.

ResMed vs.

ResMed (NYSE:RMD) and Boston Scientific (NYSE:BSX) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, dividends, analyst recommendations, institutional ownership, earnings and community ranking.

ResMed presently has a consensus target price of $202.80, suggesting a potential downside of 3.51%. Boston Scientific has a consensus target price of $76.70, suggesting a potential downside of 0.58%. Given Boston Scientific's stronger consensus rating and higher probable upside, analysts clearly believe Boston Scientific is more favorable than ResMed.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ResMed
0 Sell rating(s)
3 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.70
Boston Scientific
0 Sell rating(s)
2 Hold rating(s)
19 Buy rating(s)
1 Strong Buy rating(s)
2.95

In the previous week, ResMed had 3 more articles in the media than Boston Scientific. MarketBeat recorded 14 mentions for ResMed and 11 mentions for Boston Scientific. ResMed's average media sentiment score of 1.22 beat Boston Scientific's score of 1.10 indicating that ResMed is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
ResMed
10 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Boston Scientific
7 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Boston Scientific has higher revenue and earnings than ResMed. ResMed is trading at a lower price-to-earnings ratio than Boston Scientific, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ResMed$4.22B7.31$897.56M$6.5132.29
Boston Scientific$14.71B7.70$1.59B$1.1964.82

ResMed has a net margin of 20.91% compared to Boston Scientific's net margin of 12.06%. ResMed's return on equity of 24.43% beat Boston Scientific's return on equity.

Company Net Margins Return on Equity Return on Assets
ResMed20.91% 24.43% 15.70%
Boston Scientific 12.06%16.39%9.08%

ResMed has a beta of 0.68, indicating that its share price is 32% less volatile than the S&P 500. Comparatively, Boston Scientific has a beta of 0.81, indicating that its share price is 19% less volatile than the S&P 500.

55.0% of ResMed shares are owned by institutional investors. Comparatively, 89.1% of Boston Scientific shares are owned by institutional investors. 1.2% of ResMed shares are owned by company insiders. Comparatively, 0.5% of Boston Scientific shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Boston Scientific received 587 more outperform votes than ResMed when rated by MarketBeat users. Likewise, 69.39% of users gave Boston Scientific an outperform vote while only 52.93% of users gave ResMed an outperform vote.

CompanyUnderperformOutperform
ResMedOutperform Votes
415
52.93%
Underperform Votes
369
47.07%
Boston ScientificOutperform Votes
1002
69.39%
Underperform Votes
442
30.61%

Summary

Boston Scientific beats ResMed on 12 of the 19 factors compared between the two stocks.

Get ResMed News Delivered to You Automatically

Sign up to receive the latest news and ratings for RMD and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RMD vs. The Competition

MetricResMedSurgical & medical instruments IndustryMedical SectorNYSE Exchange
Market Cap$31.09B$3.89B$5.15B$17.63B
Dividend Yield0.91%1.80%5.26%3.56%
P/E Ratio32.299.42130.4521.79
Price / Sales7.3167.642,249.1914.48
Price / Cash27.1147.1731.6715.72
Price / Book7.484.254.904.92
Net Income$897.56M$4.42M$109.40M$975.80M
7 Day Performance-1.44%-1.42%-0.75%-1.39%
1 Month Performance-1.70%-1.30%0.46%-1.48%
1 Year Performance-2.11%-15.30%2.89%8.99%

ResMed Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BSX
Boston Scientific
4.4603 of 5 stars
$77.14
-0.4%
$76.70
-0.6%
+50.4%$113.17B$14.71B64.8248,000Positive News
MDT
Medtronic
4.8201 of 5 stars
$81.96
-1.4%
$93.00
+13.5%
-2.1%$108.82B$32.36B29.8095,000Insider Selling
BDX
Becton, Dickinson and Company
4.6977 of 5 stars
$234.90
-1.9%
$280.17
+19.3%
-6.6%$67.89B$19.37B51.7473,000Short Interest ↑
Analyst Revision
EW
Edwards Lifesciences
4.3691 of 5 stars
$87.00
+1.0%
$95.06
+9.3%
+3.4%$52.43B$6.00B37.5019,800Positive News
DXCM
DexCom
4.9353 of 5 stars
$116.90
+0.3%
$140.94
+20.6%
-6.0%$46.49B$3.62B75.429,600Analyst Downgrade
Short Interest ↑
Positive News
IDXX
IDEXX Laboratories
4.3661 of 5 stars
$506.20
-0.4%
$580.38
+14.7%
+12.3%$41.81B$3.66B49.0011,000Positive News
STE
STERIS
3.6341 of 5 stars
$225.38
+0.3%
$241.60
+7.2%
+8.9%$22.29B$5.14B59.0018,179Positive News
HOLX
Hologic
4.8132 of 5 stars
$72.90
-1.4%
$85.60
+17.4%
-6.3%$17.01B$3.96B37.196,990Short Interest ↑
Positive News
BAX
Baxter International
4.9613 of 5 stars
$32.88
-0.1%
$44.42
+35.1%
-21.7%$16.75B$14.81B6.3260,000
PODD
Insulet
4.4885 of 5 stars
$192.16
+0.1%
$239.18
+24.5%
-32.1%$13.46B$1.70B58.233,000Analyst Forecast
Insider Selling
News Coverage

Related Companies and Tools

This page (NYSE:RMD) was last updated on 6/12/2024 by MarketBeat.com Staff

From Our Partners